Episode Details

Back to Episodes
Episode 373: January 2023 Retinal Physician Discussion Focusing on Coding for Geographic Atrophy Injections, Private Equity Perspectives, Biomarkers for Diabetic Retinopathy, Early Worsening of Diabetic Retinopathy

Episode 373: January 2023 Retinal Physician Discussion Focusing on Coding for Geographic Atrophy Injections, Private Equity Perspectives, Biomarkers for Diabetic Retinopathy, Early Worsening of Diabetic Retinopathy

Published 3 years, 5 months ago
Description

Drs. Safa Rahmani, Kat Talcott, and Sarwar Zahid join to discuss the January 2023 issue of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include the coding for geographic atrophy injections, private equity perspectives, biomarkers for diabetic retinopathy, and early worsening of diabetic retinopathy with anti-diabetic medications.


Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Allergan, Apellis, DORC, Genentech, Ocuterra, and Regeneron. Dr. Talcott is a consultant for Genentech, Regenxbio, and Zeiss. Dr. Rahmani has received research funding from Regeneron. Dr. Zahid has no relevant disclosures.

You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us